-+ 0.00%
-+ 0.00%
-+ 0.00%
AstraZeneca Imfinzi-enfortumab vedotin combo wins FDA priority review for muscle-invasive bladder cancer
Share
Listen to the news
AstraZeneca Imfinzi-enfortumab vedotin combo wins FDA priority review for muscle-invasive bladder cancer
  • AstraZeneca won FDA Priority Review for Imfinzi with enfortumab vedotin in muscle-invasive bladder cancer patients ineligible for cisplatin.
  • Filing seeks perioperative use with neoadjuvant enfortumab vedotin before cystectomy; decision due in Q4 2026 under the PDUFA clock.
  • Application rests on Phase III VOLGA interim data showing significant gains in event-free survival, overall survival versus surgery with or without adjuvant therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 25, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending